In human studies, a recent report investigating the use of the rapalog sirolimus found that it inhibited transplant rejection whilst promoting prolonged efficacy of anti-PD-1 ICB in transplant patients treated for cancer [208]. The gene discussed is PDCD1; the disease is cancer.